Warren and Hawley Push to Break Up Vertically Integrated Health Giants

Senators Elizabeth Warren and Josh Hawley introduced a proposal designed to dismantle the vertical structures that combine insurers, pharmacy chains and pharmacy benefit managers under single corporate umbrellas. The draft forbids a parent company from simultaneously owning entities that deliver medical services and the organizations that negotiate or pay for those services, while also blocking wholesalers from holding provider management arms. Enforcement would rest with the Federal Trade Commission, Health and Human Services and the Justice Department, and the measure includes civil penalties and private- and government-initiated remedies to compel compliance. Lawmakers framed the policy as a competition and affordability initiative, arguing that integrated ownership can divert patients toward affiliate providers and distort price-setting mechanisms. The measure singles out business models exemplified by firms that pair insurance operations with PBMs and retail pharmacy networks, citing concerns that these structures may impede independent pharmacies and independent providers. Industry leaders have defended integrated models as efficient and consumer-oriented, setting the stage for a legal and policy clash if the bill advances. The proposal follows prior bipartisan scrutiny of PBMs and recent federal steps to tighten rules on middlemen in drug pricing, and it lands amid heightened attention to health costs ahead of a pivotal midterm election. If enacted, the law would likely trigger divestitures, restructurings or new compliance programs across major health corporations, and it would prompt immediate litigation over the scope of antitrust authority and exemptions. Practical outcomes for drug prices and care access are uncertain: eliminating vertical integration could increase competition in some markets but also create transitional disruption that affects contracting and supply chains. The bill is as much political signaling as it is regulatory architecture, aligning populist critiques of concentrated market power with tangible statutory tools. Ultimately, the legislation elevates a central question for US health policy: whether structural separation of payment, distribution and care delivery will deliver lower costs and wider choice or simply reshape industry incentives without systemic savings.